ArticleDiscover oncology2025
Multi-omics study of prognostic models and molecular networks related to ovarian cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anatomical precision in the omics era: a proposed framework for selective para-aortic lymphadenectomy in epithelial ovarian cancer.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOvarian cancer (OV) is considered the most lethal gynecological cancer in women. Despite significant advancements in treatment and risk-stratification methods, these approaches remain far from ideal. This study aims to leverage large-scale public cohorts to identify differentially expressed prognostic genes between OV and normal ovarian tissue and evaluate their impact on patient survival.
methodsUtilizing data from extensive public cohorts and machine learning methods, we conducted a comprehensive screening to identify genes differentially expressed in ovarian cancer compared to normal ovarian tissue. We also developed a risk score for each patient based on these genes. Subsequent analyses explored the immunological profiles and genomic alterations associated with different risk scores.
resultsOur analysis revealed that a high risk score is positively correlated with poor survival in OV patients. The risk score is associated with key oncological pathways, immune-related processes, and genomic changes. Notably, patients with higher risk scores exhibited increased levels of immune cell infiltration and significant remodeling of the immune microenvironment. Furthermore, there is a strong correlation between the risk score and immune checkpoint molecules, suggesting potential benefits from immune checkpoint blockade strategies. The risk score also proved to be a stable and sensitive indicator for predicting sensitivity to various chemotherapeutic drugs.
conclusionsThrough an integrative approach, our study deciphers the prognostic, immune, and therapeutic value of the risk score in OV. This analysis highlights the importance of the risk score in predicting survival, modulating immune response, and guiding chemotherapy sensitivity, thus supporting its utility in improving personalized treatment strategies for ovarian cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.